Psychedelic Research Recap October 2024
In October we investigate discontinuation of antidepressants and psychedelic treatments, 2C-B effects, and neurofeedback and psychedelics.
Floris Wolswijk
Psychedelic Research Recap September 2024
Psychedelic research in September 2024 covered mescaline dosing, meditation, psilocybin for veterans, harmine dosing, and more
Psychedelic Research Recap July & August 2024
The psychedelic research from July and August 2024. Covering LSD follow-up, R vs S-MDMA, and false insights after psychedelics.
Psychedelic Research Recap June 2024
Psychedelic research in June 2024 investigated the coupling of psychedelics (and benzos), the role of purging, and ethical guidelines
Psychedelic Research Recap May 2024
Psychedelic research in May 2024 investigates awe in ketamine therapy, role of therapy in PAT, touch guidelines, real world impact of psychedelics, and more.
Psychedelic Research Recap April 2024
April 2024 psychedelic research explores mechanisms, addresses challenges, compares MDMA to amphetamines, reviews 5-MeO-DMT, and investigates novel therapeutic applications for seizures, personality disorders, and cluster headaches.
Getting The Ducks in a Row in Europe – The EMA Workshop on Psychedelics – Day 1
Europe explores the future of Psychedelic Medicine in a workshop led by the European Medicines Agency (EMA) – First Day
Psychedelic Research Recap March 2024
In this recap of the latest psychedelic research from March 2024 we look at meditation, SSRIs, and safety of psychedelics, and 17 more studies.
Psychedelic Research Recap February 2024
What happens if psychedelics become a regular part of therapy? In a way, that is what the majority of research on psychedelics is trying to answer. Studies analysing the safety, to mapping out the effectiveness in various domains, including those featured here in February, help us understand psychedelics as medicines.
Blossom Pro: Research Briefing #5 – Microdosing for ADHD, PAT in Switzerland, and Repeated Psilocybin Dosing
How can microdosing support people who experience ADHD, and does it work better than conventional medications? The first article explores this across two studies. We then venture into the heart of Europe, where psychedelic-assisted psychotherapy has been legally possible for the last decade (again). Finally, I’ll focus on the flexible repeated dosing in a trial with psilocybin for depression.